The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029.

The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market.

Fill This Form and get the Sample Copy of This Report: https://www.sdki.jp/sample-request-58848


"The Final Report will cover the impact analysis of COVID-19 on this industry (Global Non-Alcoholic Steatohepatitis Drugs Market)."

However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD.

A few notable trends include surging market penetration for NASH major drugs, increasing prevalence of NASH, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in e-commerce pharmaceutical products sales.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs.

Fill This Form and get the Sample Copy of This Report: https://www.sdki.jp/sample-request-58848


"The Final Report will cover the impact analysis of COVID-19 on this industry (Global Non-Alcoholic Steatohepatitis Drugs Market)."

Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.

Scope of the report:
The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.
The major regional markets (the U.S., Europe and Rest of World) have been analyzed.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.
Key Target Audience:
NAFLD/NASH Drugs Manufacturers
Chemical Suppliers
End Users (Hospital, Medical centers, Clinical Institutes)
Healthcare Consulting Firms
Investment Banks
Government Bodies & Regulating Authorities

Table of Content

1. Market Overview
1.1 Introduction
1.2 Causes & Symptoms
1.3 Diagnosis
1.4 Treatment
1.5 Off-Label Treatment
1.6 Therapeutic Treatment
2. Impact of COVID-19
2.1 Rise in Number of COVID-19 Cases
2.2 Growth in Government Spending on Healthcare
2.3 Rise in Application of Biomarkers
2.4 Impact on NASH Therapeutics Clinical Trials